Innate Pharma 주식 가격. IPHA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

3.00

매수가

2.89

매도가

3.05

거래량

13,593,143

1.47 일간 변동폭 3.5107

0.00 52주 범위 0.00

market_cap

241.36M

전일 종가

1.55

개장가

1.50

최근 거래 시간

마지막 거래 시간

재정 규모

US$ 32,049,169

VWAP

2.3577

평균 볼륨(3m)

발행 주식

80,453,282

배당수익률

주가수익률

-20.19

주당순이익(EPS)

-0.09

매출

61.64M

순이익

-7.57M

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therap... Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others. 더 보기

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.innate-pharma.com

본부

Marseille, Bouches-du-rhone, Fra

설립됨

Innate Pharma SA is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker IPHA. The last closing price for Innate Pharma was US$1.55. Over the last year, Innate Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Innate Pharma currently has 80,453,282 shares in issue. The market capitalisation of Innate Pharma is US$124.70 million. Innate Pharma has a price to earnings ratio (PE ratio) of -20.19.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanés

Les résultats mettent en évidence des signes précoces prometteurs selon lesquels lacutamab pourrait aider à soulager certains des symptômes les plus éprouvants des lymphomes T cutanés...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

가장 활성
% 상승자
% 패자

기호	가격	볼륨
WKEYWISeKey International Holdings AG	US$ 7.84 (139.02%)	75.53M
IPHAInnate Pharma SA	US$ 3.00 (93.55%)	13.59M
AVLDirexion Daily AVGO Bull 2X Shares	US$ 33.67 (48.92%)	658.55k
LOOPLoop Industries Inc	US$ 1.8092 (47.09%)	82.56M
AVGXDefiance Daily Target 2X Long AVGO ETF	US$ 31.49 (46.67%)	3.55M
RPTXRepare Therapeutics Inc	US$ 1.765 (-55.54%)	4.59M
INOInovio Pharmaceuticals Inc New	US$ 2.31 (-38.56%)	9.59M
XXII22nd Century Group Inc	US$ 0.048 (-34.69%)	41.72M
FLGCFlora Growth Corporation	US$ 1.30 (-34.34%)	4.01M
WTOUTime Limited	US$ 0.281 (-32.74%)	3.79M
NVDANVIDIA Corporation	US$ 134.25 (-2.25%)	231.23M
SOUNSoundHound AI Inc	US$ 16.905 (23.66%)	159.56M
TRUGTruGolf Holdings Inc	US$ 0.6794 (30.93%)	141.89M
RGTIRigetti Computing Inc	US$ 7.155 (19.85%)	124.45M
AVGOBroadcom Inc	US$ 224.80 (24.43%)	121.33M